Quick Answer
Tempest Therapeutics, Inc. reported Diluted EPS of $6.33 per share (loss) for fiscal year 2025.
Tempest Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$6.33 | +67.5% |
| 2024 | -$19.50 | -920.9% |
| 2023 | -$1.91 | +38.2% |
| 2022 | -$3.09 | +58.6% |
| 2021 | -$7.47 | +81.8% |
| 2020 | -$41.03 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.79 | +85.2% | +61.8% |
| June 30, 2025 | -$2.07 | +62.5% | +34.5% |
| March 31, 2025 | -$3.16 | +31.6% | +40.6% |
| September 30, 2024 | -$5.32 | -1008.3% | +3.6% |
| June 30, 2024 | -$5.52 | -922.2% | -19.5% |
| March 31, 2024 | -$4.62 | -740.0% | -862.5% |
| September 30, 2023 | -$0.48 | +27.3% | +11.1% |
| June 30, 2023 | -$0.54 | +31.6% | +1.8% |
- Tempest Therapeutics, Inc. showed an increase of +67.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Tempest Therapeutics, Inc.’s diluted eps has grown by 84.6% (from $41.03 per share (loss) to $6.33 per share (loss)).
- The most recent figure is from Tempest Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: